Bio-Rad Laboratories (NYSE:BIO) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Bio-Rad Laboratories (NYSE:BIO) released its quarterly earnings results on Thursday. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08), FiscalAI reports. The company had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.89 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. Bio-Rad Laboratories’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.54 EPS.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Updated 2026 guidance tightened: the company now expects currency‑neutral revenue growth of -3% to +0.5%, full‑year non‑GAAP gross margin of 53–54% and operating margin of 10–12%, citing a ~$11M Q1 impact and an ongoing headwind from the Middle East conflict that could materially pressure revenue and margins for 2026.
• Digital PCR momentum: ddPCR instrument revenue grew 24% in Q1, the new QX700 has >99% of assays enabled ahead of plan, and the Stilla acquisition is on track to be accretive by mid‑year, supporting future consumables pull‑through and share gains.
• Accounting volatility: reported net loss of $527M was driven by a $562M fair‑value decline in the company’s Sartorius equity stake, while non‑GAAP net income was $51M ($1.89 EPS), separating market valuation swings from core operating results.
• Operational efficiency initiatives include manufacturing select life‑science instruments In China for China, procurement and manufacturing rationalization, and R&D reprioritization toward higher‑return areas (digital PCR, oncology assays and embedded AI) to improve agility and margins.
• Balance sheet and capital allocation: Q1 free cash flow was $78M, cash and short‑term investments were $1.565B, the company repurchased ~$48M of stock in the quarter and has ~$237M remaining under its buyback authorization.

Bio-Rad Laboratories Price Performance

Shares of BIO stock traded up $4.50 during trading hours on Thursday, reaching $279.65. The stock had a trading volume of 650,153 shares, compared to its average volume of 246,573. Bio-Rad Laboratories has a 12 month low of $211.43 and a 12 month high of $343.12. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $7.55 billion, a PE ratio of 10.02 and a beta of 1.16. The stock’s fifty day simple moving average is $277.81 and its 200 day simple moving average is $298.20.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in BIO. Geneos Wealth Management Inc. boosted its stake in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the period. Los Angeles Capital Management LLC bought a new stake in Bio-Rad Laboratories during the fourth quarter worth about $47,000. Itau Unibanco Holding S.A. lifted its stake in Bio-Rad Laboratories by 57.6% during the fourth quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock worth $60,000 after purchasing an additional 72 shares during the last quarter. State of Wyoming bought a new stake in Bio-Rad Laboratories during the fourth quarter worth about $74,000. Finally, Quarry LP lifted its stake in Bio-Rad Laboratories by 131.5% during the third quarter. Quarry LP now owns 287 shares of the medical research company’s stock worth $80,000 after purchasing an additional 163 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BIO. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $339.75.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.